Screener / SEC EDGAR /CIK 0001088856 /10-K filed Feb 24, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Corcept Therapeutics Inc CORT

Compare with peers Embed
SEC comment letters, last 20 years

5 reviews of CORT's filings by SEC staff

UPLOAD and CORRESP
Reviews 5 latest letter Sep 18, 2025
Questions asked 8 each answered in the company's own letter
No closing letter 0 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 5 UPLOAD
  2. 2. Questions in them 8 numbered comments
  3. 3. Company replies 5 CORRESP
  4. 4. Reviews closed 5 of 5 closing letter

Half the closed reviews took 17 days or less from the first letter to the closing letter.

Form 10-K for the Fiscal Year Ended December 31, 2024

2025-09-18 to 2025-12-11 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2025-12-11
Segments
Notes to Consolidated Financial Statements
SEC asked
Basis of Presentation and Summary of Significant Accounting Policies Segment Reporting, page F-12 1. Please confirm that you will provide the segment disclosures required by ASC 28010-50, as amended by ASU 2023-07, in your future filings. Refer to ASC 280-10-5020 for single reportable segment entity requirements.
CORT answered
The Company respectfully confirms that it will include in future filings with the Commission the segment disclosures required by ASC 280-10-50, as amended by ASU 2023-07, substantially as follows:

Segment Reporting

Based on the way we organize our business, make decisions, allocate resources and assess performance, we have determined that Corcept has a single reportable segment – the discovery, development and commercialization of pharmaceutical products. Our

Chief Executive Officer, Joseph K.
Rest of the answer

Belanoff, M.D., is the Chief Operating Decision Maker (“CODM”), with ultimate responsibility for its activities and performance. He bases his decisions as CODM on regular reviews of our consolidated balance sheets (including cash, cash equivalents and investments and liabilities), statements of income (including revenue, expense and net income) and statements of cash flows, as well as regular reviews of expenses that are consistent with those disclosed in our consolidated statements of income.

Read in the reply

Also in this review: closing letter, 2025-12-11

Schedule 14A

2023-08-07 to 2023-08-24 · 3 questions · 1 letter from the SEC, 1 from the company
Review closed 2023-08-24
Executive pay
Definitive Proxy Statement on Schedule 14A filed April 14, 2023 · Pay versus Performance, page 24
SEC asked (1)
We note your statement in footnote (2) to your pay versus performance table that “[i]n general, Compensation Actually Paid is calculated as Summary Compensation Table total compensation adjusted to include the fair market value of equity awards as of December 31 of the applicable year or, if earlier, the vesting date (rather than the grant date).” Since some of the required calculations involve changes in fair
Rest of the question

market value from the prior year end, rather than fair market value at year end, if you choose to include disclosure summarizing Regulation S-K Item 402(v), please ensure that the correct requirements are discussed.

CORT answered
The Company acknowledges the Staff’s comment and hereby advises the Staff that in the event the Company chooses to include disclosure summarizing Regulation S-K Item 402(v) in its future filings that include the Company’s pay versus performance table, it will ensure that the correct requirements are discussed.
Read in the reply
Definitive Proxy Statement on Schedule 14A filed April 14, 2023 · Pay versus Performance, page 24
SEC asked (2)
We note footnote (5) to your pay versus performance table states the Nasdaq US Benchmark TR Index is your Peer Group for purposes of your Total Stockholder Return comparison. This index appears to be a broad equity market index used for purposes of Regulation S-K Item 201(e)(1)(i) and not the index or issuers used by you for purposes of Regulation S-K Item 201(e)(1)(ii).
Rest of the question

Please ensure that your peer group total shareholder return column and related disclosure uses the same index or issuers used for purposes of Regulation S-K Item 201(e)(1)(ii) or the companies you use as a peer group for purposes of disclosure under Regulation S-K Item 402(b).

CORT answered
The Company acknowledges the Staff’s comment and hereby advises the Staff that the Company will include the referenced disclosure in its future filings that include the Company’s pay versus performance table.
Read in the reply
Definitive Proxy Statement on Schedule 14A filed April 14, 2023 · Pay versus Performance, page 24
SEC asked (3)
It appears that you have not provided the relationship disclosures required by Regulation S-K Item 402(v)(5). Please ensure that you provide this required disclosure in its entirety. Although you may provide this information graphically, narratively, or a combination of the two, this disclosure must be separate from the pay versus performance table required by Regulation S-K Item 402(v)(1) and must provide a clear
Rest of the question

description of each separate relationship indicated in Regulation S-K Item 402(v)(5)(i)-(iv). Please note, it is not sufficient to state that no relationship exists, even if a particular measure is not used in setting compensation.

CORT answered
The Company acknowledges the Staff’s comment and hereby advises the Staff that the Company will include the referenced disclosure required by Regulation S-K Item 402(v)(5) in its future filings.
Read in the reply

Also in this review: closing letter, 2023-08-24

Form 10-K for the Fiscal Year Ended December 31, 2020

2021-11-10 to 2021-11-16 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2021-11-16
Controls
SEC asked
We note your disclosures in management's report on internal control over financial reporting refer to disclosure controls and procedures. Please amend the filing to provide a revised management's report on internal control over financial reporting to properly include a statement identifying the framework used by management in such evaluation, as well as management's assessment conclusion, in accordance with Item
Rest of the question

308(a) of Regulation S-K. You may file an abbreviated amendment that is limited to the cover page, an explanatory note, the complete text of Item 9A, a signature page, and the required officer certifications.

CORT answered
The Company respectfully acknowledges the Staff’s comment and will amend its 2020 Form

10-K to provide revised Item 9A disclosure, including a revised management’s report on internal control over financial reporting which properly includes a statement identifying the framework used by management in such evaluation, as well as management’s assessment conclusion.

The Company’s proposed revised disclosure for Item 9A(b) is as follows (Item 9(a) and (c) will be the same as those respective sections in the 2020 Form 10-K):

Our management is responsible for establishing and maintaining adequate
Rest of the answer

internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Our internal control system is designed to provide reasonable assurance regarding the preparation and fair presentation of externally-reported consolidated financial statements in accordance with U.S. GAAP. As discussed in Item 9A(a) above, internal control systems, no matter how well designed, have inherent limitations and can provide only reasonable assurance that their objectives have been met.

As of December 31, 2020, our management conducted an evaluation, under the supervision and with the participation of our Chief

Executive Officer and Chief Financial Officer, of the effectiveness of our internal control over financial reporting based upon the framework in “Internal Control-Integrated Framework (2013)” issued by the Committee of Sponsoring

Organizations of the Treadway Commission. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our internal control over financial reporting was effective as of December 31, 2020.

Our independent registered public accounting firm has issued an attestation report on our internal control over financial reporting. It is set forth below.

The Company intends to file the amendment to its 2020 Form 10-K on November 15, 2021.

Read in the reply
In its next report

First report after the company's reply of Nov 15, 2021: 10-K filed Feb 15, 2022 ↗, against the 10-K filed Feb 23, 2021 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2021-11-16

Form 10-K for the fiscal year ended June 30, 2019

2020-11-10 to 2020-12-23 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2020-12-23
Controls
Item 4. Controls and Procedures, page 20
SEC asked
We note your statement that your disclosure controls and procedures provide a reasonable level of assurance that the information required to be disclosed in your Quarterly Reports on Form 10-Q was communicated to management, so as to allow timely decisions regarding required disclosure.
Rest of the question

In future Form 10-Q filings please revise to state clearly, if true, that your disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives and that your principal executive and principal financial officer concluded that your disclosure controls and procedures are effective at the reasonable assurance level. In the alternative, you may remove the reference to the level of assurance provided by your disclosure controls and procedures.

CORT answered
The Company respectfully acknowledges the Staff’s comment and in future Form

10-K and Form 10-Q filings will state clearly, if true, that the Company’s disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives and that the Company’s principal executive and principal financial officer concluded that the Company’s disclosure controls and procedures are effective at the reasonable assurance level.

The Company’s proposed subsequent disclosure is as follows:

As of [the end of the period covered by this report], our management conducted an
Rest of the answer

evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of [the end of the period covered by this report], our disclosure controls and procedures were effective to provide reasonable assurance that the information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to the officers who certify our financial reports and to the members of the Company’s senior management and board of directors as appropriate to allow timely decisions regarding required disclosure at the reasonable assurance level.

Read in the reply
In its next report

First report after the company's reply of Dec 14, 2020: 10-K filed Feb 23, 2021 ↗, against the 10-K filed Feb 24, 2020 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2020-12-23

Filing review

2017-09-12 to 2017-09-25 · 2 questions · 1 letter from the SEC, 1 from the company
Review closed 2017-09-25
RevenueResults discussion (MD&A)
Business · License Agreements, page 6
SEC asked (1)
Please confirm that in future filings you will disclose the royalty based on net revenues you are required to pay and the termination provisions under your license agreement with the University of Chicago. With respect to the termination provisions, we note your disclosure on page 25 that if the University of Chicago were to terminate your licenses, you may not be able to commercialize any cortisol modulators for
Rest of the question

the treatment of triplenegative breast cancer or castration-resistant prostate cancer. In addition, please confirm that you will file the license agreement as an exhibit to your next Form 10-K. Alternatively, please provide us with an analysis supporting your determination that the agreement is not a required exhibit. See Item 601(b)(10) of Regulation S-K.

CORT answered
The Company acknowledges the Staff’s comment and respectfully advises the Staff that the license agreement with the

University of Chicago relates solely to the use of cortisol modulators in combination therapy for the treatment of triple-negative breast cancer and castration-resistant prostate cancer. While both triple-negative breast and castration-resistant prostate tumor types are potential targets for cortisol modulation therapy, the Company’s currently proposed treatments for these tumor types are still years away from being clinically proven.
Rest of the answer

Thus, the time at which any products arising from the patents covered by the license agreement with the University of Chicago could result in net revenue to the Company and thereby trigger the payment of royalties to the University of Chicago — even if the Company’s clinical development efforts are successful and proceed expeditiously — is also still years away. Given this long timeline and the uncertainty regarding whether royalty payments, if any, under the license agreement would be material to the Company, the Company does not believe that the specific details of the royalty or termination provisions of the license agreement with the University of Chicago are material information to an investor at this time. The Company also respectfully advises the Staff that it has disclosed on page F-13 of its Form 10-K that the Company’s annual and milestone payments pursuant to the license agreement with the University of Chicago are not material and are creditable against future royalties.

For the foregoing reasons, the Company has concluded that its license agreement with the University of Chicago is not required to be filed as an exhibit to its Form 10-K or any other filing, as it is not material to the Company and the Company is not “substantially dependent” on this agreement within the meaning of Item 601(b)(10) of Regulation S-K. If the license agreement with the University of Chicago does become material to the Company at a later time, then the Company will file this agreement as an exhibit to the appropriate periodic report at such time.

Read in the reply
Management's Discussion and Analysis of Financial Condition and Results of Operations · Results of Operations, page 36
SEC asked (2)
We note your disclosure that the change in revenues was driven by “an increase in sales volume and price increases.” It appears from statements in your fourth quarter 2016, first quarter 2017, and second quarter 2017 earnings calls that you increased prices at January 1, 2016 and 2017 but that you had no other price increases in 2016 or 2017 to date.
Rest of the question

We note your statement in the second quarter 2017 earnings call that the increase in revenues from the first to the second quarter in 2017 was “entirely due to increased Korlym’s sales volume as there was no price increase in the second quarter.” In future filings, please separately discuss the volume and price changes, and quantify the impact of each, if practicable. Please refer to Item 303(a)(3)(iii) of Regulation S-K. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

CORT answered
The Company respectfully acknowledges the Staff’s comment. In future filings, the Company will separately discuss any material volume and price changes in accordance with Item 303(a)(3)(iii) of Regulation S-K and will quantify the impact of each, if practicable.
Read in the reply

Also in this review: closing letter, 2017-09-25

Letters without questions

Other letters

UPLOAD and CORRESP
2 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 17 letters filed since 2017-04-25. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CORT/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.